Safety and Tolerability of Adaptive Escalating Multiple Doses (Three Times Daily) of a Soluble Guanylate Cyclase (sGC) Activator Inhale, BAY 1211163, as Inhalation in Intubated and Mechanically Ventilated Adult Patients With Moderate and Severe Acute Respiratory Distress Syndrome (ARDS). A Pilot (Phase Ib), First in Patient, Open Label Study
Latest Information Update: 25 Sep 2024
At a glance
- Drugs BAY 1211163 (Primary)
- Indications Adult respiratory distress syndrome
- Focus Adverse reactions
- Sponsors Bayer
- 19 Sep 2023 Status changed from active, no longer recruiting to discontinued.
- 11 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 08 May 2023 Planned End Date changed from 27 Oct 2023 to 26 Apr 2024.